Tuvonralimab is under clinical development by Qilu Puget Sound Biotherapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tuvonralimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tuvonralimab (PSB-205) is under development for the treatment of relapsed/refractory malignant solid tumors including squamous and non-squamous non-small cell lung cancer (NSCLC), recurrent or metastatic cervical cancer, nasopharyngeal carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma, locally advanced or metastatic gastric or gastroesophageal carcinoma, colon carcinoma, small cell lung cancer, advanced urothelial cancer, metastatic colorectal cancer, metastatic melanoma, soft tissue sarcoma, bone sarcoma, metastatic renal cell carcinoma. The drug candidate is a bi-specific antibody product that contains a mixture of unique anti-PD-1 and anti-CTLA4 monoclonal antibodies produced by a single cell line via the company's proprietary MabPair technology. It is administered through intravenous drip route.
Qilu Puget Sound Biotherapeutics overview
Qilu Puget Sound Biotherapeutics (Sound Biologics) is a biotech company. The company develops treatments for cancer.
For a complete picture of Tuvonralimab’s drug-specific PTSR and LoA scores, buy the report here.